Apollo Hospitals Enterprise Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 21.2%)
- Efficient capital deployment (ROCE 17.4%)
Concerns
- High premium to book value (P/B 12.3x)
Today's Price Action
Apollo Hospitals Enterprise Limited closed at ₹8,137, matching the previous close with a flat 0 % change. The day’s turnover of 7,63,953 shares is identical to the 20‑day average volume, indicating that trading activity remains consistent with recent liquidity patterns.
Valuation Snapshot
The stock trades at a price‑to‑earnings multiple of 52.8, while the broader healthcare sector shows a neutral (0) P/E, reflecting that Apollo Hospitals carries a premium on earnings relative to its peers. A price‑to‑book ratio of 0.0 together with a return on equity of 21.2 % points to a strong equity return despite a book‑value‑based valuation that appears compressed.
Key Levels to Watch
The current price sits near the lower end of the 52‑week range, which stretched from a low of ₹6,680 to a high of ₹9,327, suggesting limited headroom before re‑testing the year‑low. Open‑interest data (not provided) would typically be examined for any clustering around the ₹8,000–₹8,200 zone, which could act as a near‑term support or resistance pivot.
Chart Pattern
In the daily candlestick chart, a shooting star formed two sessions ago, followed by a bearish harami the next day. Both patterns emerged on the 1‑day timeframe and signal a potential shift in short‑term price momentum, as each represents a bearish reversal configuration.
Data Summary
Key metrics for Apollo Hospitals Enterprise Limited include a flat close at ₹8,137, a consistent 20‑day average volume of 7,63,953 shares, and a 52.8× P/E versus a sector P/E of zero. The company exhibits a 21.2 % ROE, a 0.0 P/B, and a market cap currently reported as ₹0 Cr, with the stock positioned near the lower bound of its ₹6,680–₹9,327 52‑week range.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,335 | ₹1.0L Cr | 36.6 | 2.87 | 11.2 | 13 | 0.19 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
APOLLOHOSP · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 29.33% | 29.33% | 29.33% | 29.33% | 29.33% | 29.34% |
| FII | 46.25% | 45.63% | 43.92% | 45.37% | 45.27% | 42.74% |
| DII | 18.87% | 19.55% | 21.13% | 19.94% | 19.97% | 22.29% |
| Public | 5.32% | 5.26% | 5.38% | 5.12% | 5.21% | 5.41% |
| Govt | 0.23% | 0.23% | 0.23% | 0.23% | 0.23% | 0.23% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Dividend - Rs 10 Per Sh
To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters
Interim Dividend - Rs 10 Per Sh
Dividend - Rs 10 Per Share
Interim Dividend - Rs 9 Per Share
Record: 14 Feb 2025
Annual General Meeting/Dividend - Rs 10 Per Share
Record: 16 Aug 2024
Interim Dividend - Rs 6 Per Share
Annual General Meeting/Dividend - Rs 9 Per Share
Record: 18 Aug 2023
Latest News
All newsApollo Hospitals proposes corporate restructuring via scheme of arrangement
*Apollo Hospitals proposes corporate restructuring via scheme of arrangement.* The move aims to streamline operations and improve governance. No financial impact or change in shareholding pattern is expected. Regulatory approvals will be sought in due course. 📊 *STOCKS:* APOLLOHOSP | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Restructuring
Apollo Hospitals proposes scheme of arrangement for corporate restructuring
*Apollo Hospitals proposes a scheme of arrangement for corporate restructuring.* Additional details have been disclosed under the NSE corporate filing. The move aims to streamline operations and improve governance. No financial impact disclosed yet. 📊 *STOCKS:* APOLLOHOSP | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #Restructuring
Zydus ties up with Apollo to expand cancer test access
*Zydus ties up with Apollo to expand cancer test access* — Zydus Lifesciences has signed an MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection (MCD) test across India. The collaboration aims to enhance early cancer screening in tier-2 and tier-3 cities. The test is currently available in **15 cities** and plans to scale to **50 cities** by 2027. 📊 *STOCKS:* ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Partnership
Apollo Hospitals announces general corporate updates
*Apollo Hospitals announces general corporate updates.* No specific financial figures or strategic changes disclosed. The filing provides routine information without material impact. Investors advised to await detailed disclosures. 📊 *STOCKS:* $APOLLOHOSP | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #corporate
Apollo Hospitals files certificate under Regulation 74(5) for Sep 2026
*Apollo Hospitals files certificate under Regulation 74(5) for Sep 2026.* This is a routine compliance filing with the NSE, disclosing shareholding patterns as required under SEBI regulations. No financial or operational impact is expected from this update. Such filings are standard for listed companies on a quarterly basis. 📊 *STOCKS:* $APOLLOHOSP | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Regulation74
Apollo Sindoori Hotels holds AGM; scrutiny report filed
*Apollo Sindoori Hotels holds AGM; scrutiny report filed* — Apollo Sindoori Hotels Limited has submitted the scrutinizers' report of its Annual General Meeting held on **September 28, 2026**, to the stock exchange. The filing is a post-meeting compliance requirement and confirms procedural completion. No financial updates or material decisions were disclosed. 📊 *STOCKS:* $APOLLOHOSP | 🏢 *SECTOR:* Realty | #LOWIMPACT #AGM
MSCI August 2026 rebalancing adds four, drops three stocks
*MSCI August 2026 rebalancing adds four, drops three stocks*. MSCI includes **APOLLOHOSP**, **PERSISTENT**, **DEEPAKNTR**, and **ATGL** effective August 2026. Exits include **BEL**, **MOTHERSUMI**, and **ZENSARTECH**. The move may trigger passive fund inflows into new entrants and outflows from deleted stocks. 📊 *STOCKS:* APOLLOHOSP, PERSISTENT, DEEPAKNTR, ATGL, BEL, MOTHERSUMI, ZENSARTECH | 🏢 *SECTOR:* Indices | #MEDIUMIMPACT #MSCI
Apollo Hospitals issues general updates via NSE filing
*Apollo Hospitals issues general updates via NSE filing*. No specific financial or operational details were disclosed in the filing. The update does not indicate any material event or change. Routine corporate communication likely related to compliance or internal matters. 📊 *STOCKS:* APOLLOHOSP | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #CorporateUpdate
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6.5K Cr 2.7% | ₹6.3K Cr 7.9% | ₹5.8K Cr 4.5% | ₹5.6K Cr 1.2% | ₹5.5K Cr 1.1% | ₹5.6K Cr 9.9% | ₹5.1K Cr 2.9% | ₹4.9K Cr |
| Op. Profit | ₹965 Cr 2.6% | ₹941 Cr 10.4% | ₹852 Cr 10.6% | ₹770 Cr 1.0% | ₹762 Cr 6.6% | ₹816 Cr 20.9% | ₹675 Cr 5.5% | ₹640 Cr |
| OPM | 15.0% 0.0% | 15.0% 0.0% | 15.0% 7.1% | 14.0% 0.0% | 14.0% 6.7% | 15.0% 15.4% | 13.0% 0.0% | 13.0% |
| Net Profit | ₹516 Cr 4.5% | ₹494 Cr 12.0% | ₹441 Cr 6.5% | ₹414 Cr 9.2% | ₹379 Cr 4.3% | ₹396 Cr 25.3% | ₹316 Cr 22.5% | ₹258 Cr |
| EPS (₹) | 34.93 5.2% | 33.19 10.3% | 30.1 11.1% | 27.1 4.7% | 25.89 1.7% | 26.34 24.1% | 21.23 20.3% | 17.65 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹25.2K Cr 15.8% | ₹21.8K Cr 14.4% | ₹19.1K Cr 14.7% | ₹16.6K Cr 13.3% | ₹14.7K Cr 38.9% | ₹10.6K Cr 6.1% | ₹11.2K Cr 16.9% | ₹9.6K Cr 16.7% | ₹8.2K Cr 13.6% | ₹7.3K Cr |
| Expenses | ₹21.4K Cr 14.3% | ₹18.8K Cr 12.6% | ₹16.7K Cr 14.6% | ₹14.5K Cr 16.6% | ₹12.5K Cr 32.4% | ₹9.4K Cr 2.4% | ₹9.7K Cr 13.0% | ₹8.5K Cr 14.9% | ₹7.4K Cr 14.1% | ₹6.5K Cr |
| Op. Profit | ₹3.8K Cr 24.6% | ₹3.0K Cr 26.7% | ₹2.4K Cr 15.9% | ₹2.1K Cr 5.7% | ₹2.2K Cr 92.0% | ₹1.1K Cr 28.3% | ₹1.6K Cr 48.7% | ₹1.1K Cr 33.6% | ₹801 Cr 9.1% | ₹734 Cr |
| OPM | 15.0% 7.1% | 14.0% 7.7% | 13.0% 8.3% | 12.0% 20.0% | 15.0% 36.4% | 11.0% 21.4% | 14.0% 27.3% | 11.0% 10.0% | 10.0% 0.0% | 10.0% |
| Other Income | ₹207 Cr 6.8% | ₹222 Cr 80.5% | ₹123 Cr 64.0% | ₹75 Cr 79.6% | ₹368 Cr 257.3% | ₹103 Cr 53.6% | ₹222 Cr 753.8% | ₹26 Cr 8.3% | ₹24 Cr 60.0% | ₹60 Cr |
| Interest | ₹450 Cr 1.7% | ₹458 Cr 2.0% | ₹449 Cr 17.8% | ₹381 Cr 0.5% | ₹379 Cr 15.6% | ₹449 Cr 15.8% | ₹533 Cr 63.0% | ₹327 Cr 10.8% | ₹295 Cr 14.8% | ₹257 Cr |
| Depreciation | ₹876 Cr 15.6% | ₹758 Cr 10.3% | ₹687 Cr 11.7% | ₹615 Cr 2.3% | ₹601 Cr 4.9% | ₹573 Cr 7.6% | ₹620 Cr 56.6% | ₹396 Cr 10.3% | ₹359 Cr 14.3% | ₹314 Cr |
| PBT | ₹2.7K Cr 30.5% | ₹2.0K Cr 47.8% | ₹1.4K Cr 20.6% | ₹1.1K Cr 27.5% | ₹1.6K Cr 614.0% | ₹221 Cr 66.5% | ₹660 Cr 76.9% | ₹373 Cr 118.1% | ₹171 Cr 23.0% | ₹222 Cr |
| Tax % | 25.0% 3.8% | 26.0% 18.8% | 32.0% 45.5% | 22.0% 26.7% | 30.0% 21.1% | 38.0% 11.8% | 34.0% 27.7% | 47.0% 27.7% | 65.0% 58.5% | 41.0% |
| Net Profit | ₹2.0K Cr 33.1% | ₹1.5K Cr 61.0% | ₹935 Cr 10.8% | ₹844 Cr 23.8% | ₹1.1K Cr 708.8% | ₹137 Cr 68.3% | ₹432 Cr 116.0% | ₹200 Cr 233.3% | ₹60 Cr 54.2% | ₹131 Cr |
| EPS (₹) | 135.04 34.3% | 100.56 60.9% | 62.5 9.7% | 56.97 22.4% | 73.42 601.9% | 10.46 68.0% | 32.7 92.8% | 16.96 100.9% | 8.44 46.9% | 15.88 |
| Div Payout | 15.0% 15.4% | 13.0% 50.0% | 26.0% 0.0% | 26.0% 62.5% | 16.0% 44.8% | 29.0% 61.1% | 18.0% 48.6% | 35.0% 40.7% | 59.0% 55.3% | 38.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹72 Cr 0.0% | ₹72 Cr 0.0% | ₹72 Cr 0.0% | ₹72 Cr 0.0% | ₹72 Cr 0.0% | ₹72 Cr 2.9% | ₹70 Cr 0.0% | ₹70 Cr 0.0% | ₹70 Cr 0.0% | ₹70 Cr |
| Reserves | ₹9.0K Cr 10.8% | ₹8.1K Cr 18.6% | ₹6.9K Cr 12.0% | ₹6.1K Cr 10.4% | ₹5.6K Cr 22.5% | ₹4.5K Cr 38.6% | ₹3.3K Cr 0.2% | ₹3.3K Cr 2.6% | ₹3.2K Cr 1.9% | ₹3.2K Cr |
| Borrowings | ₹8.0K Cr 1.6% | ₹7.9K Cr 47.5% | ₹5.3K Cr 23.1% | ₹4.3K Cr 6.5% | ₹4.1K Cr 2.2% | ₹4.2K Cr 15.7% | ₹3.6K Cr 2.1% | ₹3.7K Cr 7.2% | ₹3.4K Cr 9.7% | ₹3.1K Cr |
| Other Liabilities | ₹4.9K Cr 6.6% | ₹4.6K Cr 2.1% | ₹4.5K Cr 15.1% | ₹3.9K Cr 8.9% | ₹3.6K Cr 35.8% | ₹2.6K Cr 39.6% | ₹4.4K Cr 101.7% | ₹2.2K Cr 12.6% | ₹1.9K Cr 15.1% | ₹1.7K Cr |
| Total Liabilities | ₹21.9K Cr 6.3% | ₹20.6K Cr 23.3% | ₹16.7K Cr 16.1% | ₹14.4K Cr 8.7% | ₹13.3K Cr 16.4% | ₹11.4K Cr 0.9% | ₹11.3K Cr 23.2% | ₹9.2K Cr 6.6% | ₹8.6K Cr 6.1% | ₹8.1K Cr |
Assets | ||||||||||
| Fixed Assets | ₹11.3K Cr 2.5% | ₹11.0K Cr 13.7% | ₹9.7K Cr 13.4% | ₹8.5K Cr 2.7% | ₹8.3K Cr 22.4% | ₹6.8K Cr 8.8% | ₹7.4K Cr 49.2% | ₹5.0K Cr 4.4% | ₹4.8K Cr 4.0% | ₹4.6K Cr |
| CWIP | ₹1.0K Cr 11.4% | ₹921 Cr 5.5% | ₹873 Cr 43.1% | ₹610 Cr 1226.1% | ₹46 Cr 80.3% | ₹234 Cr 0.8% | ₹236 Cr 71.3% | ₹822 Cr 15.4% | ₹712 Cr 105.2% | ₹347 Cr |
| Investments | ₹3.0K Cr 20.9% | ₹2.5K Cr 152.2% | ₹986 Cr 71.8% | ₹574 Cr 29.7% | ₹816 Cr 39.2% | ₹1.3K Cr 209.4% | ₹434 Cr 6.1% | ₹462 Cr 31.3% | ₹352 Cr 13.3% | ₹406 Cr |
| Other Assets | ₹6.7K Cr 6.5% | ₹6.2K Cr 19.7% | ₹5.2K Cr 10.8% | ₹4.7K Cr 14.8% | ₹4.1K Cr 35.1% | ₹3.0K Cr 4.7% | ₹3.2K Cr 9.9% | ₹2.9K Cr 5.1% | ₹2.8K Cr 0.0% | ₹2.8K Cr |
| Total Assets | ₹21.9K Cr 6.3% | ₹20.6K Cr 23.3% | ₹16.7K Cr 16.1% | ₹14.4K Cr 8.7% | ₹13.3K Cr 16.4% | ₹11.4K Cr 0.9% | ₹11.3K Cr 23.2% | ₹9.2K Cr 6.6% | ₹8.6K Cr 6.1% | ₹8.1K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹2.1K Cr 11.3% | ₹1.9K Cr 39.4% | ₹1.4K Cr 18.8% | ₹1.7K Cr 34.1% | ₹1.3K Cr 2.2% | ₹1.3K Cr 42.9% | ₹905 Cr 68.5% | ₹537 Cr 13.8% | ₹623 Cr 4.4% | ₹597 Cr |
| Investing CF | ₹-3.4K Cr 120.1% | ₹-1.5K Cr 79.3% | ₹-857 Cr 14.7% | ₹-747 Cr 15.1% | ₹-880 Cr 204.5% | ₹-289 Cr 59.4% | ₹-711 Cr 75.6% | ₹-405 Cr 64.8% | ₹-1.2K Cr 29.7% | ₹-888 Cr |
| Financing CF | ₹1.3K Cr 524.1% | ₹-311 Cr 50.9% | ₹-633 Cr 20.1% | ₹-792 Cr 132.9% | ₹-340 Cr 62.6% | ₹-910 Cr 323.3% | ₹-215 Cr 99.1% | ₹-108 Cr 122.6% | ₹477 Cr 44.5% | ₹330 Cr |
| Net Cash Flow | ₹73 Cr 1.4% | ₹72 Cr 163.7% | ₹-113 Cr 171.5% | ₹158 Cr 259.1% | ₹44 Cr 53.2% | ₹94 Cr 570.0% | ₹-20 Cr 183.3% | ₹24 Cr 146.2% | ₹-52 Cr 233.3% | ₹39 Cr |
| Free Cash Flow | ₹439 Cr 44.1% | ₹785 Cr 211.5% | ₹252 Cr 75.9% | ₹1.0K Cr 6.1% | ₹984 Cr 25.8% | ₹782 Cr 235.6% | ₹233 Cr 377.4% | ₹-84 Cr 82.6% | ₹-46 Cr 88.3% | ₹-393 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51d 6.3% | 48d 2.0% | 49d 11.4% | 44d 4.3% | 46d 39.4% | 33d 15.4% | 39d 5.4% | 37d 2.6% | 38d 5.6% | 36d |
| Inventory Days | 16d 5.9% | 17d 0.0% | 17d 19.0% | 21d 31.3% | 16d 67.3% | 49d 6.5% | 46d 9.8% | 51d 8.5% | 47d 4.1% | 49d |
| Days Payable | 72d 18.2% | 88d 7.3% | 82d 3.8% | 79d 6.8% | 74d 23.3% | 60d 7.1% | 56d 1.8% | 55d 7.8% | 51d 22.7% | 66d |
| Cash Conv. Cycle | -6d 73.9% | -23d 43.8% | -16d 14.3% | -14d 16.7% | -12d 154.5% | 22d 24.1% | 29d 12.1% | 33d 2.9% | 34d 78.9% | 19d |
| Working Capital Days | -6d 68.4% | -19d 1800.0% | -1d 120.0% | 5d 225.0% | -4d 50.0% | -8d 166.7% | -3d 137.5% | 8d 70.4% | 27d 68.8% | 16d |
| ROCE | 17.0% 13.3% | 15.0% 7.1% | 14.0% 17.6% | 17.0% 112.5% | 8.0% 42.9% | 14.0% 40.0% | 10.0% 42.9% | 7.0% 12.5% | 8.0% 11.1% | 9.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Apollo Hospitals Enterprise Limited
Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country.
HealthcareHealthcare Services